Greenwich LifeSciences extends share lock-up for directors and investors to January 31, 2027, amid ongoing Phase III clinical trial.
Quiver AI Summary
Greenwich LifeSciences, Inc. announced that its Board of Directors has extended the lock-up period for shares owned by directors, officers, and pre-IPO investors until January 31, 2027, following the Company's IPO. During this lock-up, these stakeholders cannot sell their shares unless modifications are made by the Board. After this date, sales will be subject to a leak-out plan, which can restrict the number of shares sold daily. The Board retains the flexibility to modify these terms, especially in light of significant developments such as data releases or strategic transactions. CEO Snehal Patel highlighted the Company’s progress in its Phase III clinical trial, FLAMINGO-01, including substantial enrollment increases and interest from prominent healthcare institutions, suggesting a promising outlook for future negotiations and opportunities.
Potential Positives
- The extension of the lock-up period for directors, officers, and pre-IPO investors to January 31, 2027, demonstrates confidence in the company's long-term strategy and stability.
- Increased enrollment and event rate in the Phase III clinical trial FLAMINGO-01 suggests positive momentum and growing interest in the company's immunotherapy product GLSI-100.
- The potential for strategic partnerships and financial transactions, indicated by the CEO's attendance at major conferences, may enhance the company's resources and market position.
Potential Negatives
- The extension of the lock-up period for shares owned by directors, officers, and pre-IPO investors may signal a lack of confidence in the company's stock performance, potentially raising concerns among investors.
- The inability for key stakeholders to sell their shares until January 31, 2027, may lead to liquidity issues and could deter new investors from entering the market.
- Dependence on the Board's discretion to modify share selling restrictions raises concerns about transparency and unpredictability in governance, which could negatively affect investor trust.
FAQ
What is the purpose of the FLAMINGO-01 clinical trial?
The FLAMINGO-01 clinical trial evaluates GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences.
When does the share lock-up period end?
The lock-up period for shares owned by directors and officers ends on January 31, 2027.
Who is affected by the share lock-up extension?
The lock-up extension affects the Company's directors, officers, and existing pre-IPO investors.
What is the significance of the Phase III trial's derisking?
The derisking suggests increased confidence in the trial's success and has led to heightened interest from clinicians and hospitals.
How can I learn more about Greenwich LifeSciences?
For more information, you can visit Greenwich LifeSciences' website at www.greenwichlifesciences.com or follow their Twitter.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GLSI Insider Trading Activity
$GLSI insiders have traded $GLSI stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GLSI stock by insiders over the last 6 months:
- SNEHAL PATEL (CEO and CFO) has made 5 purchases buying 7,300 shares for an estimated $97,003 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$GLSI Hedge Fund Activity
We have seen 34 institutional investors add shares of $GLSI stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NUVEEN, LLC added 88,717 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,130,982
- CREDIT AGRICOLE S A removed 87,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,089,740
- BLACKROCK, INC. added 51,994 shares (+12.0%) to their portfolio in Q2 2026, for an estimated $1,219,779
- VIRTU FINANCIAL LLC removed 28,797 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $691,703
- SEI INVESTMENTS CO added 26,088 shares (+inf%) to their portfolio in Q1 2026, for an estimated $626,633
- MARSHALL WACE, LLP added 25,658 shares (+inf%) to their portfolio in Q1 2026, for an estimated $616,305
- INFORMED MOMENTUM CO LLC added 21,430 shares (+inf%) to their portfolio in Q1 2026, for an estimated $514,748
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.
The Board could choose to end all or a small percentage of the 100% lock-up at any time for any reason, including prior to any data announcements, interim analyses, strategic transactions, such as an acquisition or partnership, or financial transactions, such as royalty or strategic investor transactions that provide a potential bridge to commercialization. The Board could also choose to implement a pre-determined leak-out plan and/or a 10b5-1 selling program at any time for any reason that allows for the organized independent selling of some of the locked-up shares by a third party over a specified period of time. Such decisions may or may not be announced at the time of the board's decision.
CEO Snehal Patel commented, "We attended and presented at the BIO conference in June 2026 and plan to attend the BIO-Europe conference later this year, where strategic and financing transactions can be originated or concluded. With the further derisking of the Phase III clinical trial, more than doubling of enrollment and event rate, interest from leading clinicians and hospitals in up to 200 sites in the US and Europe, screening of over 1,500 patients, and the transformation of the interim analysis into a big pharma like study similar in design to recent large breast cancer studies, we are expecting a continued up-tick in the quantity and seriousness of such discussions."
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email:
[email protected]
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email:
[email protected]
